Many new medications for type 2 diabetes have become available in the past several years, but it’s not always clear which medicine is best for which person. Dr. Ruth Hertzman-Miller, part of the Professional Education team at Joslin, is doing a research study to understand how people with type 2 diabetes and their health care providers make decisions about medications. As part of the study, Dr. Hertzman-Miller is doing an anonymous survey of adults in the United States with type 2 diabetes.
The study is sponsored by Sanofi-Aventis, the maker of Lyxumia® (lixisenatide), a new GLP-1 agonist which is currently approved in several countries and is undergoing regulatory review by the FDA in the United States. Although the study focuses specifically on why people do or don’t use the GLP-1 agonists, Dr. Hertzman-Miller hopes that what she learns will be helpful in clarifying how treatment decisions are made, leading to better treatment in general for people with type 2 diabetes, regardless of which medication they may be on.
Eligible participants will be entered in a raffle to win a free iPad. The survey link is here.